505 related articles for article (PubMed ID: 31771653)
1. The immune landscape of esophageal cancer.
Huang TX; Fu L
Cancer Commun (Lond); 2019 Nov; 39(1):79. PubMed ID: 31771653
[TBL] [Abstract][Full Text] [Related]
2. Promising immunotherapies for esophageal cancer.
Tanaka T; Nakamura J; Noshiro H
Expert Opin Biol Ther; 2017 Jun; 17(6):723-733. PubMed ID: 28366014
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for esophageal cancer: a 2019 update.
Schizas D; Charalampakis N; Kole C; Mylonas KS; Katsaros I; Zhao M; Ajani JA; Psyrri A; Karamouzis MV; Liakakos T
Immunotherapy; 2020 Feb; 12(3):203-218. PubMed ID: 32208794
[TBL] [Abstract][Full Text] [Related]
4. The paratumoral immune cell signature reveals the potential for the implementation of immunotherapy in esophageal carcinoma patients.
Strizova Z; Snajdauf M; Stakheev D; Taborska P; Vachtenheim J; Biskup J; Lischke R; Bartunkova J; Smrz D
J Cancer Res Clin Oncol; 2020 Aug; 146(8):1979-1992. PubMed ID: 32447483
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of tumor immunosuppressive microenvironment formation in esophageal cancer.
Zhang XJ; Yu Y; Zhao HP; Guo L; Dai K; Lv J
World J Gastroenterol; 2024 Apr; 30(16):2195-2208. PubMed ID: 38690024
[TBL] [Abstract][Full Text] [Related]
6. The Clinical Application of Neoantigens in Esophageal Cancer.
Gu YM; Zhuo Y; Chen LQ; Yuan Y
Front Oncol; 2021; 11():703517. PubMed ID: 34386424
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications.
Fang P; Zhou J; Liang Z; Yang Y; Luan S; Xiao X; Li X; Zhang H; Shang Q; Zeng X; Yuan Y
Front Immunol; 2022; 13():975986. PubMed ID: 36119033
[TBL] [Abstract][Full Text] [Related]
8. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer.
Yi L; Huang P; Zou X; Guo L; Gu Y; Wen C; Wu G
Pharmacol Res; 2020 Nov; 161():105144. PubMed ID: 32810627
[TBL] [Abstract][Full Text] [Related]
9. A good start of immunotherapy in esophageal cancer.
Zhao Q; Yu J; Meng X
Cancer Med; 2019 Aug; 8(10):4519-4526. PubMed ID: 31231980
[TBL] [Abstract][Full Text] [Related]
10. [Current status and prognosis of immune checkpoint inhibitors for esophageal cancer].
Gao HJ; Shang XB; Yu ZT
Zhonghua Wai Ke Za Zhi; 2019 Oct; 57(10):77-82. PubMed ID: 31510736
[TBL] [Abstract][Full Text] [Related]
11. Emerging immunotherapy for the treatment of esophageal cancer.
Jackie Oh S; Han S; Lee W; Lockhart AC
Expert Opin Investig Drugs; 2016 Jun; 25(6):667-77. PubMed ID: 26950826
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
Alsina M; Moehler M; Lorenzen S
Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
[TBL] [Abstract][Full Text] [Related]
13. Innate Immune Cells in the Esophageal Tumor Microenvironment.
Cui K; Hu S; Mei X; Cheng M
Front Immunol; 2021; 12():654731. PubMed ID: 33995371
[TBL] [Abstract][Full Text] [Related]
14. Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens.
Liu X; Song N; Liu Y; Liu Y; Li J; Ding J; Tong Z
Cell Immunol; 2015 Jun; 295(2):77-82. PubMed ID: 25863743
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B
Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy.
Ma Y; Yu J; Ma X; Li Q; Su Q; Cao B
Asia Pac J Clin Oncol; 2024 Apr; 20(2):180-187. PubMed ID: 37171038
[TBL] [Abstract][Full Text] [Related]
17. Immune-based combination therapy for esophageal cancer.
Wang H; Xu Y; Zuo F; Liu J; Yang J
Front Immunol; 2022; 13():1020290. PubMed ID: 36591219
[TBL] [Abstract][Full Text] [Related]
18. Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy.
Zhang Y; Zhang Y; Zhang L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):281-291. PubMed ID: 30656409
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic strategies for treating esophageal adenocarcinoma: the potential of dendritic cell immunotherapy and combinatorial regimens.
Milano F; Krishnadath KK
Hum Immunol; 2008 Oct; 69(10):614-24. PubMed ID: 18703104
[TBL] [Abstract][Full Text] [Related]
20. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.
Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW
J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
